1
|
Lorzadeh A, Hammond C, Wang F, Knapp DJHF, Wong JC, Zhu JYA, Cao Q, Heravi-Moussavi A, Carles A, Wong M, Sharafian Z, Steif J, Moksa M, Bilenky M, Lavoie PM, Eaves CJ, Hirst M. Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs. BMC Biol 2022; 20:104. [PMID: 35550087 PMCID: PMC9102747 DOI: 10.1186/s12915-022-01315-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 04/28/2022] [Indexed: 12/05/2022] Open
Abstract
Background Lifelong production of the many types of mature blood cells from less differentiated progenitors is a hierarchically ordered process that spans multiple cell divisions. The nature and timing of the molecular events required to integrate the environmental signals, transcription factor activity, epigenetic modifications, and changes in gene expression involved are thus complex and still poorly understood. To address this gap, we generated comprehensive reference epigenomes of 8 phenotypically defined subsets of normal human cord blood. Results We describe a striking contraction of H3K27me3 density in differentiated myelo-erythroid cells that resembles a punctate pattern previously ascribed to pluripotent embryonic stem cells. Phenotypically distinct progenitor cell types display a nearly identical repressive H3K27me3 signature characterized by large organized chromatin K27-modification domains that are retained by mature lymphoid cells but lost in terminally differentiated monocytes and erythroblasts. We demonstrate that inhibition of polycomb group members predicted to control large organized chromatin K27-modification domains influences lymphoid and myeloid fate decisions of primary neonatal hematopoietic progenitors in vitro. We further show that a majority of active enhancers appear in early progenitors, a subset of which are DNA hypermethylated and become hypomethylated and induced during terminal differentiation. Conclusion Primitive human hematopoietic cells display a unique repressive H3K27me3 signature that is retained by mature lymphoid cells but is lost in monocytes and erythroblasts. Intervention data implicate that control of this chromatin state change is a requisite part of the process whereby normal human hematopoietic progenitor cells make lymphoid and myeloid fate decisions. Supplementary Information The online version contains supplementary material available at 10.1186/s12915-022-01315-1.
Collapse
Affiliation(s)
- A Lorzadeh
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - C Hammond
- Terry Fox Laboratory, BC Cancer, Vancouver, Canada.,Department of Medicine, UBC, Vancouver, Canada
| | - F Wang
- Terry Fox Laboratory, BC Cancer, Vancouver, Canada.,Department of Medical Genetics, UBC, Vancouver, Canada
| | - D J H F Knapp
- Terry Fox Laboratory, BC Cancer, Vancouver, Canada.,Department of Medicine, UBC, Vancouver, Canada
| | - J Ch Wong
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - J Y A Zhu
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - Q Cao
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - A Heravi-Moussavi
- Canada's Michael Smith Genome Science Centre, BC Cancer, Vancouver, Canada
| | - A Carles
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - M Wong
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - Z Sharafian
- BC Children's Hospital Research Institute, Department of Pediatrics, UBC, Vancouver, Canada
| | - J Steif
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - M Moksa
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada
| | - M Bilenky
- Canada's Michael Smith Genome Science Centre, BC Cancer, Vancouver, Canada
| | - P M Lavoie
- BC Children's Hospital Research Institute, Department of Pediatrics, UBC, Vancouver, Canada
| | - C J Eaves
- Terry Fox Laboratory, BC Cancer, Vancouver, Canada.,Department of Medicine, UBC, Vancouver, Canada.,Department of Medical Genetics, UBC, Vancouver, Canada
| | - M Hirst
- Department of Microbiology and Immunology, Michael Smith Laboratories, UBC, Vancouver, Canada. .,Canada's Michael Smith Genome Science Centre, BC Cancer, Vancouver, Canada.
| |
Collapse
|